Literature DB >> 23994535

A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.

Johanna Hynninen1, Jukka Kemppainen, Maija Lavonius, Johanna Virtanen, Jaakko Matomäki, Sinikka Oksa, Olli Carpén, Seija Grénman, Marko Seppänen, Annika Auranen.   

Abstract

OBJECTIVE: The use of tumor debulking surgery in the management of epithelial ovarian cancer (EOC), which is often disseminated in the peritoneal cavity at the time of diagnosis, has a significant impact on prognosis. We compared (18)F-fluorodeoxyglucose (FDG) positron emission tomography/contrast-enhanced computed tomography (PET/CT) to contrast-enhanced CT for the detection of dissemination into the abdominal cavity preventing successful primary debulking surgery.
METHODS: Forty-one women with EOC underwent preoperative whole-body low-dose FDG-PET/CT followed by diagnostic high dose contrast-enhanced CT scan, and the results were compared with systematically recorded surgical findings as a reference standard. Both site-based and patient-based analyses were conducted.
RESULTS: FDG-PET/CT was superior to conventional CT for the detection of carcinomatosis in subdiaphragmatic peritoneal surfaces (p=0.020) and in the bowel mesentery (p=0.001). Patient-based analysis of upper abdominal areas requiring extensive surgical procedures showed no significant differences between the two imaging methods. The sensitivity of PET/CT and CT was poor in certain areas of the peritoneal cavity (64% vs. 27% in the small bowel mesentery and 65% vs. 55% in the right upper abdomen). Extra-abdominal disease spread was detected by PET/CT in 32 patients and by CT in 25 patients.
CONCLUSIONS: PET/CT was not superior to CT for the detection of intra-abdominal disease spread. Patients with suspected EOC should be referred for upfront radical surgery regardless of the results of preoperative imaging studies. PET/CT is more effective for the detection of extra-abdominal disease than CT, but the clinical significance of this finding is unclear.
© 2013.

Entities:  

Keywords:  Operability; Ovarian cancer; PET/CT; Preoperative imaging; Staging

Mesh:

Substances:

Year:  2013        PMID: 23994535     DOI: 10.1016/j.ygyno.2013.08.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  25 in total

1.  The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.

Authors:  Jeong Won Lee; Arthur Cho; Jae-Hoon Lee; Mijin Yun; Jong Doo Lee; Young Tae Kim; Won Jun Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-23       Impact factor: 9.236

Review 2.  Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.

Authors:  Natalia Rodriguez Gómez-Hidalgo; Bertha Alejandra Martinez-Cannon; Alpa M Nick; Karen H Lu; Anil K Sood; Robert L Coleman; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2015-03-28       Impact factor: 5.482

Review 3.  Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients.

Authors:  Lucas Minig; Cristina Zorrero; Pablo Padilla Iserte; Andres Poveda
Journal:  World J Methodol       Date:  2015-12-26

4.  Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer.

Authors:  Hyun Hoon Chung; Maria Lee; Hee-Seung Kim; Jae-Weon Kim; Noh-Hyun Park; Yong Sang Song; Gi Jeong Cheon
Journal:  Eur Radiol       Date:  2017-06-07       Impact factor: 5.315

5.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

6.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  J Clin Oncol       Date:  2016-08-08       Impact factor: 44.544

Review 7.  Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.

Authors:  Kazuhiro Kitajima; Yasuhiko Ebina; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2014-04-18       Impact factor: 2.374

Review 8.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

9.  Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.

Authors:  Jean M Hansen; Anil K Sood; Robert L Coleman; Shannon N Westin; Pamela T Soliman; Pedro T Ramirez; Bryan M Fellman; Kathleen M Schmeler; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2018-10-23       Impact factor: 5.482

Review 10.  [Clinical evaluation of female pelvic tumors : Application fields of integrated PET/MRI].

Authors:  J Grueneisen; L Umutlu
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.